Lanean...
Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
BACKGROUND: Between 2009 and 2012, there was a worldwide shortage of agalsidase-β for the treatment of Fabry disease. Therefore, alternative treatments were needed, including switching to a different enzyme-replacement therapy. PURPOSE: This is an ongoing observational study assessing the effects of...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4189383/ https://ncbi.nlm.nih.gov/pubmed/24651606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/gim.2014.28 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|